Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q2 EPS of ($0.37), $0.04 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $5.18 million versus the consensus estimate of $4.58 million.

For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.